Literature DB >> 9749367

Structure-based design of ligands for protein basic domains: application to the HIV-1 Tat protein.

A V Filikov1, T L James.   

Abstract

A methodology has been developed for designing ligands to bind a flexible basic protein domain where the structure of the domain is essentially known. It is based on an empirical binding free energy function developed for highly charged complexes and on Monte Carlo simulations in internal coordinates with both the ligand and the receptor being flexible. HIV-1 encodes a transactivating regulatory protein called Tat. Binding of the basic domain of Tat to TAR RNA is required for efficient transcription of the viral genome. The structure of a biologically active peptide containing the Tat basic RNA-binding domain is available from NMR studies. The goal of the current project is to design a ligand which will bind to that basic domain and potentially inhibit the TAR-Tat interaction. The basic domain contains six arginine and two lysine residues. Our strategy was to design a ligand for arginine first and then a superligand for the basic domain by joining arginine ligands with a linker. Several possible arginine ligands were obtained by searching the Available Chemicals Directory with DOCK 3.5 software. Phytic acid, which can potentially bind multiple arginines, was chosen as a building block for the superligand. Calormetric binding studies of several compounds to methylguanidine and Arg-/Lys-containing peptides were performed. The data were used to develop an empirical binding free energy function for prediction of affinity of the ligands for the Tat basic domain. Modeling of the conformations of the complexes with both the superligand and the basic domain being flexible has been carried out via Biased Probability Monte Carlo (BPMC) simulations in internal coordinates (ICM 2.6 suite of programs). The simulations used parameters to ensure correct folding, i.e., consistent with the experimental NMR structure of a 25-residue Tat peptide, from a random starting conformation. Superligands for the basic domain were designed by joining together two molecules of phytic acid with peptidic and peptidomimetic linkers. The linkers were refined by varying the length and side chains of the linking residues, carrying out BPMC simulations, and evaluation of the binding free energy for the best energy conformation. The dissociation constant of the best ligand designed is estimated to be in the low- to mid-nanomolar range.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9749367     DOI: 10.1023/a:1007949625270

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  26 in total

1.  Fragments of the HIV-1 Tat protein specifically bind TAR RNA.

Authors:  K M Weeks; C Ampe; S C Schultz; T A Steitz; D M Crothers
Journal:  Science       Date:  1990-09-14       Impact factor: 47.728

2.  RNA binding by the tat and rev proteins of HIV-1.

Authors:  J Karn; C Dingwall; J T Finch; S Heaphy; M J Gait
Journal:  Biochimie       Date:  1991-01       Impact factor: 4.079

3.  Atomic solvation parameters applied to molecular dynamics of proteins in solution.

Authors:  L Wesson; D Eisenberg
Journal:  Protein Sci       Date:  1992-02       Impact factor: 6.725

4.  Mutational analysis of the conserved basic domain of human immunodeficiency virus tat protein.

Authors:  J Hauber; M H Malim; B R Cullen
Journal:  J Virol       Date:  1989-03       Impact factor: 5.103

5.  Rapid measurement of binding constants and heats of binding using a new titration calorimeter.

Authors:  T Wiseman; S Williston; J F Brandts; L N Lin
Journal:  Anal Biochem       Date:  1989-05-15       Impact factor: 3.365

6.  Solution structure of a bovine immunodeficiency virus Tat-TAR peptide-RNA complex.

Authors:  J D Puglisi; L Chen; S Blanchard; A D Frankel
Journal:  Science       Date:  1995-11-17       Impact factor: 47.728

7.  Hydrogen-bonding contacts in the major groove are required for human immunodeficiency virus type-1 tat protein recognition of TAR RNA.

Authors:  F Hamy; U Asseline; J Grasby; S Iwai; C Pritchard; G Slim; P J Butler; J Karn; M J Gait
Journal:  J Mol Biol       Date:  1993-03-05       Impact factor: 5.469

8.  Inhibition of human immunodeficiency virus type 1 Tat activity by coexpression of heterologous trans activators.

Authors:  R Carroll; B M Peterlin; D Derse
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

9.  The structure of the human immunodeficiency virus type-1 TAR RNA reveals principles of RNA recognition by Tat protein.

Authors:  F Aboul-ela; J Karn; G Varani
Journal:  J Mol Biol       Date:  1995-10-20       Impact factor: 5.469

10.  HIV-1 Tat protein promotes formation of more-processive elongation complexes.

Authors:  R A Marciniak; P A Sharp
Journal:  EMBO J       Date:  1991-12       Impact factor: 11.598

View more
  4 in total

1.  Identification of ligands for RNA targets via structure-based virtual screening: HIV-1 TAR.

Authors:  A V Filikov; V Mohan; T A Vickers; R H Griffey; P D Cook; R A Abagyan; T L James
Journal:  J Comput Aided Mol Des       Date:  2000-08       Impact factor: 3.686

2.  Computational stabilization of human growth hormone.

Authors:  Anton V Filikov; Robert J Hayes; Peizhi Luo; Diane M Stark; Cheryl Chan; Anirban Kundu; Bassil I Dahiyat
Journal:  Protein Sci       Date:  2002-06       Impact factor: 6.725

Review 3.  Phytate: impact on environment and human nutrition. A challenge for molecular breeding.

Authors:  Lisbeth Bohn; Anne S Meyer; Søren K Rasmussen
Journal:  J Zhejiang Univ Sci B       Date:  2008-03       Impact factor: 3.066

Review 4.  Evolution of In Silico Strategies for Protein-Protein Interaction Drug Discovery.

Authors:  Stephani Joy Y Macalino; Shaherin Basith; Nina Abigail B Clavio; Hyerim Chang; Soosung Kang; Sun Choi
Journal:  Molecules       Date:  2018-08-06       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.